Grifols stock costs EUR 9.93 ahead of November results
Published on 10/07/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols (ISIN ES0171996087) was trading at EUR 9.93 at Lang & Schwarz on October 7, 2026 at 10:09 a.m. CEST, plus 0.40 percent versus the prior close of EUR 9.89. The next quarterly results are listed for November 10, 2026 by finanzen.ch.
First-half profit reaches EUR 227 million
According to Grifols, revenue in the first half of 2026 increased 2.60 percent at constant exchange rates to EUR 3.6 billion. Net profit for the same period rose 28.70 percent to EUR 227 million.
The earnings mix matters because the improvement came alongside lower costs and reduced financial expenses. The company also reported first-half earnings per share of EUR 0.33, giving the profit increase a direct per-share reference.
Debt remains the investor test
OCU Inversiones wrote on September 29, 2026 that Grifols still needed to generate sufficient resources for sustained debt reduction. Its analysis put debt at EUR 11.30 per share and identified the Biopharma division as 88.00 percent of revenue.
That combination creates a clear test for the November update. Profit growth of 28.70 percent is constructive, but the balance-sheet burden means cash generation and financing costs remain as important as revenue growth for the equity story.
Results date sets the next checkpoint
The November 10, 2026 reporting date gives the market a defined checkpoint for judging whether the first-half improvement continued. Investors will have fresh evidence on revenue, profit and the company's progress on debt reduction when Grifols reports.
Grifols stock holds near EUR 10
At Lang & Schwarz, Grifols stock was trading at EUR 9.93 on October 7, 2026 at 10:09 a.m. CEST, plus 0.40 percent against the prior close of EUR 9.89 on October 6, 2026. The further course of trading is shown by the continuously updated real-time quote of Grifols stock.
Grifols stock facts
- Company: Grifols, S.A.
- ISIN: ES0171996087
- Ticker: GRF.MC
- Primary exchange: BME
- Price Lang & Schwarz as of October 7, 2026 at 10:09 a.m. CEST: EUR 9.93
- Change versus prior close: plus 0.40 percent
- Prior close Lang & Schwarz (October 6, 2026): EUR 9.89
- Sector / Industry: Health Care / Drug Manufacturers - General
- Next earnings date: November 10, 2026
